<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412607</url>
  </required_header>
  <id_info>
    <org_study_id>BWI40036</org_study_id>
    <nct_id>NCT00412607</nct_id>
  </id_info>
  <brief_title>Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia</brief_title>
  <acronym>VT-CoA</acronym>
  <official_title>NaviStar ThermoCool Catheter for Endocardial RF Ablation in Patients With Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective is to provide additional corroborative safety and efficacy data for the
      Navistar ThermoCool catheter for the treatment of subjects with ischemic Ventricular
      Tachycardia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, non-randomized, single-arm, multi-center condition of approval
      evaluation. The device is currently FDA approved for commercial distribution. Subjects with
      ischemic ventricular tachycardia will be considered for the condition of approval study. This
      study will be conducted at up to 30 centers in a minimum of 249 evaluable subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation.</measure>
    <time_frame>12-month post ablation</time_frame>
    <description>The long-term primary safety endpoint is the percentage of subjects that expire from all-cause mortality within 12-months post ablation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Subjects Who Experienced Cardiovascular-specific Adverse Events (CSAE) Within Seven Days of the Ablation Procedure.</measure>
    <time_frame>Seven days post ablation procedure</time_frame>
    <description>The acute primary safety endpoint is the percentage of subjects who experienced cardiovascular-specific adverse events (CSAE) within seven days of the ablation procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieved Acute Success</measure>
    <time_frame>Duration from post-procedure to hospital discharge, up to 2 days</time_frame>
    <description>Acute success was defined as the subjects receiving successful ablation of all targeted Ventricular Tachycardia (VT) and no recurrence prior to hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Achieved Chronic Effectiveness</measure>
    <time_frame>6-month follow up</time_frame>
    <description>Chronic effectiveness is defined as subjects without recurrence of sustained monomorphic ventricular tachycardia (SMVT) at 6 month follow-up. For subjects with Implantable Cardioverter Defibrillator (ICD), recurrences of SMVT were defined as appropriate ICD shock therapies. For subjects without ICDs, recurrences of SMVT were recorded in the follow-up visits form. Besides SMVT, recurrence of incessant VT was also captured in this study. Recurrence of incessant VT was recorded up to 6 month post ablation procedure but not beyond.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieved Long-term Efficacy Success</measure>
    <time_frame>3-year follow up</time_frame>
    <description>Long-term success is defined as patient-reported non-recurrence of Ventricular Tachycardia (VT) at the12-month, second year, and third year phone follow-ups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction at 6 Month From Baseline</measure>
    <time_frame>6-month follow up</time_frame>
    <description>Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 6 month follow up. LVEF is a measure of the percentage of blood leaving heart each time it contracts. Baseline LVEF data were collected at pre ablation procedure, at hospital discharge, and at the 6-month follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>NaviStar ThermoCool Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAVISTAR® THERMOCOOL® Catheter</intervention_name>
    <description>The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease</description>
    <arm_group_label>NaviStar ThermoCool Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented spontaneous episodes of sustained ventricular tachycardia (must satisfy
             one)

               1. For patients with ICDs: Documented episodes must be four (4) or greater for entry
                  into the study.

               2. For patients without ICDs: Documented episodes must be two (2) or greater within
                  two (2) months and the assessment will be performed by a review of ECGs and
                  hospitalization records.

               3. Incessant VT due to prior myocardial infarction (defined as present for more than
                  one (1) hour and refractory to or immediately recurrent after administration of
                  antiarrhythmic medication and cardioversion).

          2. Spontaneous occurrence of symptomatic ventricular tachycardia despite antiarrhythmic
             drug therapy or ICD intervention.

          3. Left ventricular ejection fraction &gt; 10% as estimated by echocardiography, contrast
             ventriculography or radionuclide imaging within the previous ninety (90) days.

          4. Age eighteen (18) years or older.

          5. Signed Patient Informed consent form.

          6. Able and willing to comply with all pre-, post-, and follow-up testing requirements.

        Exclusion Criteria:

          1. Definite protruding left ventricular thrombus on pre-ablation echocardiogram.

          2. Myocardial infarction within the preceding two (2) months. Patients with incessant VT
             (defined as present for more than one (1) hour and refractory to or immediately
             recurrent after administration of antiarrhythmic medication and cardioversion) may be
             enrolled if their MI is at least three (3) weeks old.

          3. Patients with idiopathic VT.

          4. Other disease process likely to limit survival to less than twelve (12) months.

          5. Class IV heart failure.

          6. Serum creatinine of &gt; 2.5 mg/dl.

          7. Thrombocytopenia (defined as platelet count &lt;80,000) or coagulopathy.

          8. Contraindication to heparin.

          9. Women who are pregnant.

         10. Cardiac surgery (i.e. ventriculotomy, atriotomy) within the past two (2) months.
             Patients with incessant VT (present 50% of the time with intervention for a period &gt;12
             h) may be enrolled if their surgery is at least three (3) weeks old.

         11. Acute illness or active systemic infection.

         12. Unstable angina.

         13. Severe aortic stenosis or flail mitral valve.

         14. Uncontrolled heart failure.

         15. Significant congenital anomaly or medical problem that, in the opinion of the
             Principal Investigator, would preclude enrollment in the study.

         16. Enrolled in an investigational study evaluating another device or drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arrhythmia Consultants</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research - St. David's</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <results_first_submitted>September 23, 2014</results_first_submitted>
  <results_first_submitted_qc>October 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2014</results_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on April 3, 2007. Subject enrollment was completed on May 19, 2009 after reaching the minimum enrollment criteria of two hundred forty-nine (249) subjects. Subject follow-up was completed on June 8, 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NAVISTAR THERMOCOOL Catheter</title>
          <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Study Catheter</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not meet inclusion/exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects who signed the informed consent form and were eligible for inclusion in the clinical study</population>
      <group_list>
        <group group_id="B1">
          <title>NAVISTAR THERMOCOOL Catheter</title>
          <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation.</title>
        <description>The long-term primary safety endpoint is the percentage of subjects that expire from all-cause mortality within 12-months post ablation.</description>
        <time_frame>12-month post ablation</time_frame>
        <population>Safety analysis population - subjects who underwent insertion of the study catheter.</population>
        <group_list>
          <group group_id="O1">
            <title>NAVISTAR THERMOCOOL Catheter</title>
            <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation.</title>
          <description>The long-term primary safety endpoint is the percentage of subjects that expire from all-cause mortality within 12-months post ablation.</description>
          <population>Safety analysis population - subjects who underwent insertion of the study catheter.</population>
          <units>percentage of mortality</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="0" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Assumptions for sample size calculation: 10% attrition rate, Type I error of 0.05, anticipated 12-month mortality rate is 0.19, a region of indifference of 0.07, power of 0.8; the required sample size is 249 per nQuery Exact test for single proportion method.
The null hypothesis is that the 12-month mortality rate is greater than or equal to 0.26; the alternative is that the rate is less than 0.26. This hypothesis is evaluated with one-sided exact binomial test at α= 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of mortality</param_type>
            <param_value>13.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>17.5</ci_upper_limit>
            <estimate_desc>The 95% confidence interval is a one-sided with upper confidence level = 17.5% computed using the exact binomial test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieved Acute Success</title>
        <description>Acute success was defined as the subjects receiving successful ablation of all targeted Ventricular Tachycardia (VT) and no recurrence prior to hospital discharge.</description>
        <time_frame>Duration from post-procedure to hospital discharge, up to 2 days</time_frame>
        <population>Subjects in the efficacy analysis cohort who had targeted ventricular tachycardia ablated were included. Efficacy Analysis Cohort includes subjects who are enrolled and treated with the study catheter in compliance with the protocol and treated specifically for the study-related arrhythmia.</population>
        <group_list>
          <group group_id="O1">
            <title>NAVISTAR THERMOCOOL Catheter</title>
            <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieved Acute Success</title>
          <description>Acute success was defined as the subjects receiving successful ablation of all targeted Ventricular Tachycardia (VT) and no recurrence prior to hospital discharge.</description>
          <population>Subjects in the efficacy analysis cohort who had targeted ventricular tachycardia ablated were included. Efficacy Analysis Cohort includes subjects who are enrolled and treated with the study catheter in compliance with the protocol and treated specifically for the study-related arrhythmia.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects Who Experienced Cardiovascular-specific Adverse Events (CSAE) Within Seven Days of the Ablation Procedure.</title>
        <description>The acute primary safety endpoint is the percentage of subjects who experienced cardiovascular-specific adverse events (CSAE) within seven days of the ablation procedure.</description>
        <time_frame>Seven days post ablation procedure</time_frame>
        <population>Safety Analysis Cohort - defined as subjects who underwent insertion of the study catheter.</population>
        <group_list>
          <group group_id="O1">
            <title>NAVISTAR THERMOCOOL Catheter</title>
            <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects Who Experienced Cardiovascular-specific Adverse Events (CSAE) Within Seven Days of the Ablation Procedure.</title>
          <description>The acute primary safety endpoint is the percentage of subjects who experienced cardiovascular-specific adverse events (CSAE) within seven days of the ablation procedure.</description>
          <population>Safety Analysis Cohort - defined as subjects who underwent insertion of the study catheter.</population>
          <units>percentage of Adverse Event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Achieved Chronic Effectiveness</title>
        <description>Chronic effectiveness is defined as subjects without recurrence of sustained monomorphic ventricular tachycardia (SMVT) at 6 month follow-up. For subjects with Implantable Cardioverter Defibrillator (ICD), recurrences of SMVT were defined as appropriate ICD shock therapies. For subjects without ICDs, recurrences of SMVT were recorded in the follow-up visits form. Besides SMVT, recurrence of incessant VT was also captured in this study. Recurrence of incessant VT was recorded up to 6 month post ablation procedure but not beyond.</description>
        <time_frame>6-month follow up</time_frame>
        <population>Subjects in the Efficacy analysis cohort who had available chronic effectiveness outcomes were included</population>
        <group_list>
          <group group_id="O1">
            <title>NAVISTAR THERMOCOOL Catheter</title>
            <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Achieved Chronic Effectiveness</title>
          <description>Chronic effectiveness is defined as subjects without recurrence of sustained monomorphic ventricular tachycardia (SMVT) at 6 month follow-up. For subjects with Implantable Cardioverter Defibrillator (ICD), recurrences of SMVT were defined as appropriate ICD shock therapies. For subjects without ICDs, recurrences of SMVT were recorded in the follow-up visits form. Besides SMVT, recurrence of incessant VT was also captured in this study. Recurrence of incessant VT was recorded up to 6 month post ablation procedure but not beyond.</description>
          <population>Subjects in the Efficacy analysis cohort who had available chronic effectiveness outcomes were included</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieved Long-term Efficacy Success</title>
        <description>Long-term success is defined as patient-reported non-recurrence of Ventricular Tachycardia (VT) at the12-month, second year, and third year phone follow-ups.</description>
        <time_frame>3-year follow up</time_frame>
        <population>Subjects in the efficacy analysis cohort who completed 12-month, 2-year, or 3-year follow-up and had available long-term efficacy outcomes at the corresponding time points were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Total number of subjects who completed 12-month, 2-year, and 3-year follow-up respectively.</description>
          </group>
          <group group_id="O2">
            <title>Reported Recurrence</title>
            <description>Subjects reported recurrence of Ventricular Tachycardia (VT) at 12-month, 3-year follow-up visit</description>
          </group>
          <group group_id="O3">
            <title>Reported No Recurrence</title>
            <description>Subjects reported no recurrence of Ventricular Tachycardia (VT) at 12-month, 3-year follow-up visit</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieved Long-term Efficacy Success</title>
          <description>Long-term success is defined as patient-reported non-recurrence of Ventricular Tachycardia (VT) at the12-month, second year, and third year phone follow-ups.</description>
          <population>Subjects in the efficacy analysis cohort who completed 12-month, 2-year, or 3-year follow-up and had available long-term efficacy outcomes at the corresponding time points were included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12-Month Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Year Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Year Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction at 6 Month From Baseline</title>
        <description>Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 6 month follow up. LVEF is a measure of the percentage of blood leaving heart each time it contracts. Baseline LVEF data were collected at pre ablation procedure, at hospital discharge, and at the 6-month follow-up visit.</description>
        <time_frame>6-month follow up</time_frame>
        <population>Efficacy analysis cohort subjects with LVEF data available. The statistics for Baseline and 6-month were based on data available from 219 and 166 subjects respectively; the mean change was based on 163 subjects with data at both Baseline and 6-month. Hence the mean change is not the simple subtraction between Baseline and 6-month.</population>
        <group_list>
          <group group_id="O1">
            <title>NAVISTAR THERMOCOOL Catheter</title>
            <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction at 6 Month From Baseline</title>
          <description>Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 6 month follow up. LVEF is a measure of the percentage of blood leaving heart each time it contracts. Baseline LVEF data were collected at pre ablation procedure, at hospital discharge, and at the 6-month follow-up visit.</description>
          <population>Efficacy analysis cohort subjects with LVEF data available. The statistics for Baseline and 6-month were based on data available from 219 and 166 subjects respectively; the mean change was based on 163 subjects with data at both Baseline and 6-month. Hence the mean change is not the simple subtraction between Baseline and 6-month.</population>
          <units>percentage of blood leaving the heart</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Pre-Ablation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3-year follow up</time_frame>
      <desc>Serious adverse events (SAE) were those that meet the protocol definition of SAE, excluding the Cardiovascular Specific Adverse Events occurring within 7 days of the ablation procedure, but including deaths that occurred within the time frame. Deaths occurring after 7 days post-ablation were considered non-serious per the protocol definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>NAVISTAR THERMOCOOL Catheter</title>
          <description>NaviStar ThermoCool Deflectable Diagnostic/Ablation Catheter for the Treatment of Ventricular Tachycardia.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease Intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity at Device Site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>MRSA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection/Urinary Retention Retention</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>AV Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Aortoiliac Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hemodynamically Unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular node ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Biventricular assist device placed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiac - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiac stents</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chest Pain - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="78" subjects_affected="50" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Heart Transplant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Implantable Cardioverter Defibrillator maintenance</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Implantable Cardioverter Defibrillator shock - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Mitral valve regurgitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="125" subjects_affected="68" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Esophageal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chest Pain - Non cardiac</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Elective - Dental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pain - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chest Pain - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Infection - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Knee infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Methicillin-resistant Staphylococcus aureus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cardiac - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fracture - Fibula</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fracture - hip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fracture - jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fracture - pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fracture - rib</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fracture - wrist</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Spider bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Wound - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Transplant - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bowel Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cysts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pancreatic Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal - Not Elsewhere Classified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Epitaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Revascularization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="233"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact Biosense Webster for additional information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Cropper, Manager, Clinical Operations</name_or_title>
      <organization>Biosense Webster, Inc.</organization>
      <phone>(800) 729-9010 ext 8607</phone>
      <email>Kcropper@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

